XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 02, 2024
Apr. 17, 2020
Jan. 02, 2019
May 31, 2024
Apr. 30, 2021
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2020
Collaborations with Third Parties                    
First milestone payment $ 100,000                  
Time required to pay cash portion 15 days                  
Second milestone payment $ 25,000                  
Total Revenues           $ 82,385 $ 73,834 $ 147,380 $ 211,569  
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received                    
Collaborations with Third Parties                    
Total Revenues           41,000 45,400 70,400 158,400  
Collaboration revenue                    
Collaborations with Third Parties                    
Total Revenues       $ 25,000   42,111 45,532 72,193 158,511  
Minimum                    
Collaborations with Third Parties                    
Aggregate payment agreement 125,000                  
Daiichi Sankyo Europe GmbH ("DSE")                    
Collaborations with Third Parties                    
Cash payment $ 300,000                  
Daiichi Sankyo Europe GmbH ("DSE") | Minimum | Commitment Offering                    
Collaborations with Third Parties                    
Royalties 15.00%                  
Daiichi Sankyo Europe GmbH ("DSE") | Maximum | Commitment Offering                    
Collaborations with Third Parties                    
Royalties 25.00%                  
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)     $ 150,000              
Cash payment to the Company upon first commercial sales in the DSE Territory                   $ 150,000
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     15.00%              
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     25.00%              
Otsuka Pharmaceutical Co, Ltd. | Collaboration revenue                    
Collaborations with Third Parties                    
Total Revenues           0 100 0 100  
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)   $ 60,000                
Potential additional future payments   450,000                
Proceeds from milestone upon submission of a Japanese New Drug Application (JNDA) in the Otsuka Territory   $ 10,000                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   15.00%                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   30.00%                
Milestone payment upon JNDA Approval in the Otsuka Territory   $ 10,000                
Milestone payment, first national health insurance price listing   70,000                
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000                
Milestone payments related to total net sales achievements   $ 310,000                
Daiichi Sankyo Co. Ltd | Collaboration revenue                    
Collaborations with Third Parties                    
Total Revenues           100 $ 100 500 $ 100  
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Consideration cash payment         $ 30,000          
Payment to be received upon milestone         $ 175,000          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales         5.00%          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales         20.00%          
Seqirus Pty Ltd | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Total Revenues           0   300    
HLS Therapeutics | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Total Revenues           $ 1,000   $ 1,000